• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10
    • Buyers' Guide
    • Events
    • Microsites
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10
  • Buyers' Guide
  • Events
  • Microsites
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    eBook
    Top Features
    The Next Steps for Recovery and Rehab

    Scratching the Surface: A Roundtable on Coatings and Treatments

    Influencers on the Orthopedic Implant Manufacturing Market

    Innovation Iteration: Latest Advancements in Design & Prototyping

    Robot Recharge: Orthopedic Surgical Robotics Update
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    Orthopedic Innovators
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    ODT's Most-Read Stories This Week—June 25

    3Spine Inc. Receives IDE Approval for U.S. Pivotal Clinical Trial

    Volume-Based Procurement to Reduce Chinese Orthopedic Market Value

    Isto Biologics Rolls Out Influx Fibrant

    Bioventus Amends CartiHeal Acquisition Structure
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    ODT's Most-Read Stories This Week—June 25

    Isto Biologics Rolls Out Influx Fibrant

    Bioventus Amends CartiHeal Acquisition Structure

    Medtronic's LigaPASS 2.0 OK'ed for Ligament Augmentation in Spine Surgery

    Theradaptive Gains 3rd Breakthrough Designation for Spinal Fusion
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Giving Knee Replacement Surgery a Much-Needed Update

    It’s All About the Data for Supply Chain and Inventory Management

    Minimizing Risks in Minimally Invasive Surgery

    Giving Athletes Their Lives Back with Better Knee Braces

    ODT Forum '22 is Another Successful Orthopedic Tech Conference
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    AV&R

    Braxton Manufacturing

    Life Science Outsourcing Inc.

    Tiodize

    Modern Plastics
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • eBook
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Online Exclusives

    Biologics' Backbone

    The explosion in spinal fusion procedures is leading to the development of innovative regenerative treatments.

    Biologics
    A 3-D rendering of blood vessels (red) and osteoblasts (blue) are shown growing into the interconnected porosity of Biogennix's bone graft substitute. Image courtesy of Biogennix.
    Related CONTENT
    • Steri-Tek
    • Extremely Simple and Efficient
    • Extremely High Expectations
    • Researchers Uncover Aspirin’s Effects on Platelet-Rich Plasma
    • Empowering the Six Percent
    Michael Barbella, Managing Editor03.18.19
    Christopher J. Centeno, M.D., could arguably be considered the “father” of regenerative medicine. He claims, after all, to be the first person on the planet to perform stem cell injections to treat joint arthritis and various other conditions.
     
    There are several worthy contenders, including Arnie Caplan, Ph.D., pioneer of mesenchymal stem cell use (late 1980s); Philippe Henigou, developer of bone marrow concentrate treatment for bone disease (early 1990s); or Svante Gehring, M.D., the first physician to document use of platelet-rich plasma in ophthalmology (1999).
     
    Centeno, however, believes the title should go to Ohio surgeon George S. Hackett, M.D., who clinically and scientifically demonstrated the efficacy of irritating tissue to promote healing back in 1963. Hackett’s studies showed that creating controlled inflammation could increase ligament size by up to 35-40 percent (more recent analyses have confirmed those initial findings).
     
    While certainly revolutionary, Hackett’s work nevertheless was pre-dated by several thousand years: The concept of irritating tissue to promote healing actually originated with the ancient Greeks. Hippocrates reportedly treated Olympic javelin throwers with unstable shoulders by touching a “slender hot iron” to the joint’s ligaments (the heat would irritate the ligament, causing it to tighten).
     
    Chronologically speaking, then, Hippocrates is deserving of the regenerative medicine “father” title. Yet Centeno maintains that Hackett warrants a place in history, if only for his contributions to the evolution of the field.
     
    “So, is there one modern ‘father’?” Centeno, an international expert and regenerative medicine expert, asked in a blog last spring. “You could make arguments for Hernigou, Caplan, the early users of PRP, and so on. However, if you had to award the title to one person, that honor likely goes to George Hackett, who figured out that you could help ligaments heal with injections.”
     
    Regardless of its origins, regenerative medicine has become a fast-growing subsegment of the multi billion-dollar orthobiologics industry, thanks to an aging world population and advanced stem cell/gene therapy technologies in developed countries. ODT’s January/February feature “Natural Selection” examines the innovation being developed in this burgeoning sector that eventually will contribute to its double-digit annual growth over the next half-decade.
     
    Clay Shors, Ph.D., president of Irvine, Calif.-based Biogennix, shared his insights on the market for the story. His full input is provided in the following Q&A.

    Michael Barbella: Please discuss the current trends you see shaping the orthobiologics market.
    Clay Shors: There are a number of trends that are clearly making an impact in orthobiologics today. First, there is an increased awareness and attention on synthetic osteoconductive scaffold innovations. There is growing demand for synthetic bone grafting substitutes that provide better handling properties for physicians, aiding in ease-of-use and making bone grafting more efficient. Bone graft substitutes that are biocompatible, resorbable, and aid in enhancing efficiency and results are sought after right now. 
    In addition, stem cells and stem cell-related technologies are popular particularly for the patient. This is driving some orthobiologic companies to focus on and innovate completmentary technologies. Wev'e also seen a significant rise in the number of procedures that are taking place in Ambulatory Surgery Centers (ASCs) as an alternative to hospital in-patient procedures. This is a factor that is also making the use of innovative synthetic scaffolds more appealing and cost-effective.

    Barbella: What factors are driving innovation in the orthobiologics market?
    Shors: There are several elements that have been playing key roles in pushing for increased innovation in the orthobiologics space. One factor is the shifting demand from mechanical to biological solutions, which has been a meaningful trend. Another is demographics. We have a rapidly aging population with an improved life expectancy compared to generations past. Seventy is the new 50, and patients are living longer, more active, and want to live a pain-free life. All of these factors lead to new and evolving needs for an older but healthier population.
    In addition, with more people in the work environment sitting for prolonged periods of time, back pain is a lifestyle-affecting condition that has become more and more pervasive than ever before. Addictive pain medications such as OxyContin are now being less widely administered due to the current opioid addiction crisis. What we're seeing as a result is a distinct upward trend of patients opting for surgery, thereby driving further innovation.

    Barbella: What factors are impeding growth in the orthobiologics market? How can these challenges be overcome?
    Shors: One hurdle impeding growth in the orthobiologics market is the unpredictable and evolving hospital reimbursement scenario. This, and increased hospital consolidation, are current growth challenges for many orthobiologics companies today. Another obstacle that we're facing is the high costs of conducting clinical trials and the types of tests required. To this point, the increasing resources necessary for an organization in this space to achieve FDA approval in order to make certain claims can, in some cases, be cost-prohibitive.
    Although challenges exist, we believe sound science and thoughtful innovation find a way. It might just unfortunately take longer for certain solutions to come to market than consumers demand due to the hurdles discussed above.

    Barbella: What new technologies are in the works?
    Shors: At Biogennix, we're excited about the immediate future and have a healthy product roadmap, with several new products expected to hit hospital shelves within the 2019 calendar year. To note, we are currently planning on launching two new osteoconductive bone graft solutions before the end of 2019. Additionally, we are in the process of conducting necessary development and testing and are marching towards a commercial launch on both products by Q4 2019. These two products will further enhance our product offering and will offer the clinician additional alternatives to our existing portfolio.

    Barbella: Where does innovation come from in the orthobiologics market? How does Biogennix stay innovative amid all the competition?
    Shors: At Biogennix, innovation initially comes from feedback we receive from key clinicians, as well as current trends shaping not only our industry but also other areas within medicine. Amid all the competition, Biogennix can stay innovative and relevant by staying close to surgeons and distributors, understanding their needs, and staying on top of current trends inside and outside the industry. Also important is a continued focus on building and strengthening relationships with key hospital systems, group purchasing organizations, and distribution partners.

    Barbella: How does the regulatory landscape for orthobiologics differ from other sectors of the orthopedic market, and how does this affect product innovation?
    Shors: The regulatory landscape may differ somewhat for orthobiologics in terms of the higher level of scrutiny placed on new materials, technologies, and applications. For example, the distinction for orthobiologics versus many structural devices in bone reconstruction is that the regulatory approvals require demonstration of efficacy based on animal models, whereas approval of most orthopedic structural devices is typically based solely on in-vitro mechanical testing. Animal testing is generally much more expensive, has variable results, and is more time-consuming.
    Of course, with innovation comes the task of assessing and addressing new risks, which can slow down product innovation. For more agile orthobiologics companies such as Biogennix, with our solid team of product research and development experts and industry veterans, we're confident we will continue to deliver innovative products to the market.

    Barbella: What is the dominant orthobiologics application—spinal fusion, trauma repair, reconstructive surgery? What factors are driving growth in this particular application?
    Shors: Due to the increased average age of the population, as well as the lifestyle factors touched on above, the rate of spinal fusion procedures has risen rapidly over the past several decades. In addition, as structural and biologic reconstructive solutions continue to be improved and demonstrate procedural success, more patients seek these treatments, more surgeons dedicate their practices to these treatments, further contributing to the growth cycle.
    With close to half a million spinal fusion procedures performed each year and growing, spinal fusion appears to be the dominating orthobiologics application. Of course, at Biogennix, we are targeting spine, which is the largest segment. However, it is worth mentioning that there are several additional growing niche segments such as long-bone fractures, bone tumors, joint (hip and knee) revision surgeries with bone loss, small bone (foot and hand), oral-maxillofacial/plastic surgery, periodontal, and veterinary, which all require innovation when it comes to orthobiologics products.
    Lastly, with spinal fusion surgery, the drive for growth comes from an increased understanding by surgeons, patients, and the industry that fusion comes from bone regeneration. There is a growing acceptance that bone requires osteoconduction, osteogenesis, and osteoinduction. Successful regeneration comes from an equal combination of each of these factors. Reconstruction, in general, is complex and is not a one-size-fits-all science. The therapeutic constructs available for one patient might not be the best option for another. This demand for options lends itself to further innovation and orthobiologics solutions.    
    Related Searches
    • regulatory
    • hip
    • developer
    • scaffold
    Suggested For You
    Steri-Tek Steri-Tek
    Extremely Simple and Efficient Extremely Simple and Efficient
    Extremely High Expectations Extremely High Expectations
    Researchers Uncover Aspirin’s Effects on Platelet-Rich Plasma Researchers Uncover Aspirin’s Effects on Platelet-Rich Plasma
    Empowering the Six Percent Empowering the Six Percent
    Bioventus Launches OSTEOAMP SELECT Fibers Bioventus Launches OSTEOAMP SELECT Fibers
    Disrupting the Ceramic Bone Graft Substitute Sector Disrupting the Ceramic Bone Graft Substitute Sector
    Unconventional Solutions Unconventional Solutions
    Orthobiologics Orthobiologics' Precious Balance
    Orthobiologics Orthobiologics' High Reward
    Natural Selection: Biologics in Orthopedics Natural Selection: Biologics in Orthopedics
    Biogennix Names Chief Financial Officer Biogennix Names Chief Financial Officer
    Sounding Board: 2018 Reflections and Looking Ahead Sounding Board: 2018 Reflections and Looking Ahead

    Related Buyers Guide Companies

    • Steri-Tek

      Steri-Tek

      ...
      Jeff Sauter, Director Business Development 05.26.22

    • Extremities
      Extremely Simple and Efficient

      Extremely Simple and Efficient

      With more patients becoming engaged in their health, small joint device makers are designing easier, more effective treatments.
      Michael Barbella, Managing Editor 06.10.19

    • Extremities
      Extremely High Expectations

      Extremely High Expectations

      Patients are demanding small-joint solutions that eliminate pain and restore a high level of function.
      Michael Barbella, Managing Editor 06.04.19


    • Researchers Uncover Aspirin’s Effects on Platelet-Rich Plasma

      Researchers Uncover Aspirin’s Effects on Platelet-Rich Plasma

      Blood thinners have a negative effect on PRP, data show.
      Baylor College of Medicine 05.08.19

    • Empowering the Six Percent

      Empowering the Six Percent

      First female AAOS president working to remove barriers to inclusion within orthopedics.
      Michael Barbella, Managing Editor 04.26.19


    Trending
    • Professor Reinhold Ganz Is First Recipient Of Dominik C. Meyer Award
    • Bioventus Launches DUROLANE In The U.S.
    • Molybdenum-Rhenium Biomaterial: Something ‘MoRe’?
    • Former Zimmer Biomet CEO David Dvorak Named Chairman Of THINK Surgical
    • Mini MRI For Hand And Wrist Imaging Can Be Used Nearly Anywhere
    Breaking News
    • ODT's Most-Read Stories This Week—June 25
    • 3Spine Inc. Receives IDE Approval for U.S. Pivotal Clinical Trial
    • Volume-Based Procurement to Reduce Chinese Orthopedic Market Value
    • Isto Biologics Rolls Out Influx Fibrant
    • Bioventus Amends CartiHeal Acquisition Structure
    View Breaking News >
    CURRENT ISSUE

    May/June 2022

    • The Next Steps for Recovery and Rehab
    • Scratching the Surface: A Roundtable on Coatings and Treatments
    • Influencers on the Orthopedic Implant Manufacturing Market
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Florida Food Products Acquires Javo
    Roquette Launches Nutralys Rice Protein
    New IADSA Chair Lauds Explorations of Supplementation in Healthcare Policy
    Coatings World

    Latest Breaking News From Coatings World

    The Southern Society for Coatings Technology's 84th Annual Technical Conference A Success
    PPG to Showcase Specialty Automotive, Aerospace Adhesives, Sealants at Adhesives & Bonding Expo
    PPG’s New Paint for a New Start Initiative to Transform 25-plus Schools Worldwide
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most Read Stories This Week—June 25
    Magnetic Insight Announces $17 Million in Series B Funding
    BreatheSuite Adds Brad Fluegel to its Board
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pierre Fabre and Lonza Enter Manufacturing Agreement
    MasterControl and Elemental Machines Form Biomanufacturing Partnership
    Qosina Strengthens Aseptic Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Benefit Exec Joins Madison Reed's Board
    Peroni & Ellis Brooklyn Launch Fragrance Collection Inspired by Italian Spritz Cocktails
    Rhode Is Trending for June, Trendalytics Says
    Happi

    Latest Breaking News From Happi

    Spate’s Nose for the Latest Beauty Trends Says The Skunk Stripe, Collagen Serum and Waterproof Eyeshadow are Top of Mind for Consumers this Summer
    A Suitor Emerges for Revlon, SK Capital’s New Dealmaker & P&G’s Indoor Air Quality Efforts
    Wonder Curl Wins GlossWire's GlossPitch Competition
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: INX’s VC Fund, Screen Industry and Ball Top This Week’s News
    British Coatings Federation Posts Online History
    Orion Announces Price Increases, Reduced Payment Terms
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    PCMC teams with IGT, Fujifilm makes big announcement and more
    Loftware recognized as 'AIDC Company of the Year'
    Schreiner MediPharm highlights sustainability of Needle-Trap technology
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: SWM and Neenah Introduce Mativ Inc., Avgol honored for Biotransformation Technology & More
    Tranzonic Names VP of Supply Chain
    Ontex Climate Action Targets Approved by Science-Based Targets Initiative
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—June 25
    3Spine Inc. Receives IDE Approval for U.S. Pivotal Clinical Trial
    Volume-Based Procurement to Reduce Chinese Orthopedic Market Value
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: eMagin, Applied Materials, and Schott Top This Week’s Stories
    NREL Names Jennifer Logan to Leadership Team as CFO
    National Grid Renewables Orders 2 GW of First Solar Modules

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login